Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand

Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement.

from Industry-Economic Times https://ift.tt/cpGJCsZ
via IFTTT